RxDoctor Payments Data

Richard Strawsburg, MD

Neurology · Valparaiso, INNPI 1851300909

Payments from drug & device makers

$10,262in general payments, 2019–2025

Across 619 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Sanofi$764
  • UCB, Inc.$446
  • Lilly USA, LLC$442
  • Pfizer$395
  • Novartis$392
  • plus $5K from 54 others

What the payments were for

  • Speaking & faculty fees$641%
  • Food & beverage$10,12699%
  • Education$721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)204$2,303
Sanofi17$764
UCB, Inc.24$446
Lilly USA, LLC25$442
Pfizer40$395
Novartis28$392
Lundbeck LLC17$374
Jazz Pharmaceuticals Inc.17$371
Neurocrine Biosciences, Inc.15$294
Genentech USA, Inc.13$286
Teva Pharmaceuticals USA, Inc.12$255
Amneal Pharmaceuticals LLC13$234
SK Life Science, Inc.10$219
EMD Serono, Inc.11$190
Otsuka America Pharmaceutical, Inc.9$172
Axsome Therapeutics, Inc.11$171
Eisai Inc.7$170
Argenx US, Inc.7$159
Acadia Pharmaceuticals Inc9$158
Banner Life Sciences, LLC8$152
Biogen7$129
Mallinckrodt Hospital Products Inc.6$128
Acorda Therapeutics, Inc8$121
Catalyst Pharmaceuticals, Inc.5$117
Neurelis, Inc.6$113
MDD US Operations, LLC6$102
TG Therapeutics, Inc.3$85
Livanova USA, Inc.5$85
Amgen3$80
Tanabe Pharma America, Inc.4$78
AstraZeneca3$74
Merz North America, Inc.4$72
Aucta Pharmaceuticals, Inc.3$68
Adamas Pharmaceuticals, Inc.4$66
Upsher-smith Laboratories LLC4$62
Scilex Pharmaceuticals Inc.3$62
Avanir Pharmaceuticals, Inc.4$61
Inspire Medical Systems, Inc.2$57
CSL Behring3$54
Abbott3$51
Sunovion Pharmaceuticals Inc.2$47
Avadel CNS Pharmaceuticals, LLC2$46
Johnson & Johnson2$45
Greenwich Biosciences, Inc.2$43
Biohaven Pharmaceuticals, Inc.2$42
Harmony Biosciences LLC1$42
Bristol Myers Squibb2$41
Philips North America LLC2$39
Assertio Therapeutics, Inc.3$39
OWP Pharmaceuticals, Inc.2$32
Idorsia Pharmaceuticals US Inc2$30
Vanda Pharmaceuticals Inc.1$26
Zyla Life Sciences, Inc.2$26
Kyowa Kirin, Inc.1$24
ANI Pharmaceuticals, Inc.1$21
Currax Pharmaceuticals LLC1$17
Merz Pharmaceuticals, LLC1$17
Boston Scientific1$16
Azurity Pharmaceuticals, Inc.1$16
Sumitomo Pharma America, Inc.2$15

How this compares

$10,262 in reported general payments places this provider in the 65th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$279,297
Medicare patients
823
Services billed
15,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab12$122,327
GammakedImmune Globul G/Gly/Iga Avg 4612$104,310
QuliptaAtogepant63$85,618
CopaxoneGlatiramer Acetate12$75,380
Emgality PenGalcanezumab-Gnlm103$74,774
BotoxOnabotulinumtoxina54$72,345
UbrelvyUbrogepant66$70,209
Nurtec OdtRimegepant Sulfate56$60,984
RexultiBrexpiprazole20$42,741
RytaryCarbidopa/Levodopa23$25,613
NeuproRotigotine28$22,725
Ajovy AutoinjectorFremanezumab-Vfrm23$19,502
Lacosamide83$15,746
Aimovig AutoinjectorErenumab-Aooe16$14,465
Rufinamide14$12,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Botox, Ubrelvy$2,303$228,172183 claims
Teva Pharmaceuticals USA, Inc.Copaxone$255$75,38012 claims
PfizerNurtec Odt, Dilantin$395$65,39776 claims
Otsuka America Pharmaceutical, Inc.Rexulti$172$42,74120 claims
Amneal Pharmaceuticals LLCRytary$234$25,61323 claims
UCB, Inc.Neupro$446$22,72528 claims
Upsher-smith Laboratories LLCTopiramate$62$1,989167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 308 neurology providers in Indiana.

Other neurology in Valparaiso

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →